Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beloteca Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The company's current prosecution involves 1 distinct examiner working in 1 distinct art unit. This indicates a centralized prosecution status for its active applications. With 1 pending office action, the company can focus its legal resources on the specific pharmaceutical claims currently under review.
GARYU, LIANKO G is the busiest examiner for the company, with 1 pending office action. Since there is only this pending action in the entire portfolio, the review by GARYU, LIANKO G is the primary focus for the company's legal team. Advancing these pharmaceutical claims requires meeting the specific criteria established by the examiner and the 1 distinct art unit. The 1 pending office action represents the company's total active engagement with the patent office.
Practitioners should prioritize the feedback from GARYU, LIANKO G to move the company's applications toward allowance. The active matter in the Biotechnology & Pharmaceuticals sector is the most significant element of the company's current intellectual property strategy. Successfully resolving the issues in this matter will be essential for the company's growth.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GARYU, LIANKO G | 1 | 66.0% | +45.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18137351 | CETRORELIX INJECTABLE LIQUID FORMULATION | GARYU, LIANKO G | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18137351 | CETRORELIX INJECTABLE LIQUID FORMULATION | GARYU, LIANKO G | 1654 | §103 | Final Rejection | — | Pending | Apr 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeloteca Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lianko G Garyu has the most, with 1 of Beloteca Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
